Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2025
0mins
Source: Globenewswire
Appointment of New Chief Medical Officer: Artiva Biotherapeutics has appointed Dr. Subhashis Banerjee as Chief Medical Officer, who brings over 20 years of experience in clinical development for autoimmune diseases, succeeding Dr. Thorsten Graef, who will remain as a strategic advisor.
Focus on AlloNK® Program: The company aims to advance its AlloNK® program, a cell therapy designed for B-cell depletion in autoimmune diseases, leveraging Dr. Banerjee's expertise to enhance treatment accessibility and effectiveness in community settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
